Open AccessClinical efficacy and safety of nebulized prostacyclin in patients with sARs-CoV-2 (prospective comparative study)
Author(s) -
К. В. Жданов,
К. В. Козлов,
K. V. Kas’janenko,
С. М. Захаренко,
В. С. Сукачев,
Н. И. Львов,
Oleg V. Maltsev,
Д. В. Лавренчук,
I. I. Lapikov,
В. В. Шарабханов,
Р. М. Мухтаров,
М. А. Булыгин,
В. Г. Потапенко,
Eva Malikova,
M. N. Nepomnjashchikh,
B. B. Mursalov,
А. Р. Шералиев,
M. Yu. Pervakova,
С. В. Лапин
Publication year - 2020
Publication title -
žurnal infektologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.185
H-Index - 5
eISSN - 2499-9865
pISSN - 2072-6732
DOI - 10.22625/2072-6732-2020-12-3-34-41
Subject(s) - medicine , prostacyclin , adverse effect , platelet , proinflammatory cytokine , anesthesia , inflammation
Aim. In this study we evaluated clinical effectiveness and safety of nebulized prostacyclin in patients with Novel Coronavirus Disease (SARS-CoV-2). Materials and methods: We have included 44 male patients with moderate PCR confirmed SARS-CoV-2 infection in this study. Control group consisted of 23 patients treated with nebulized prostacyclin (PGI 2 ). besides standard therapy. We compared intensiveness and duration of infectious intoxication syndrome, duration of fever, cough as well as SpO 2 level, complete blood count and chemokine status values. Results: Statistically significant difference in duration of fever, cough, intensiveness and duration of infectious intoxication syndrome were observed. Lymphocyte and platelet counts were significantly higher in control group We have also noticed significantly lower level of proinflammatory mediators and C4-complement component in control group. Only 1 adverse effect associated with inhaled prostacyclin was reported. Conclusion. Nebulized prostacyclin showed therapeutic efficacy and good safety profile in adults with moderate COVID-19.